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Abstract
Some activities of retinoids on cellular and humoral immunity
have been described, but the available data are conflicting or
obtained at concentrations that are toxic in vivo. In this study,
we demonstrate that 13-cis-retinoic acid (13-cRA), a retinoid
well tolerated in human therapy, can suppress T cell-mediated
immunity in rats. Treatment with pharmacological concentra-
tions of 13-cRA prevented active as well as passive transfer
experimental autoimmune encephalomyelitis (EAE) and sup-
pressed lymphocyte responsiveness to T cell mitogens, suggest-
ing that the drug activity included suppression of an effector T
cell response. In addition, mitogen- and antigen-induced lym-
phocyte proliferation was inhibited in vitro in the presence of
concentrations of 13-cRA equivalent to or less than those
achieved in vivo, further suggesting that the prevention ofEAE
was due to a suppressive activity on T cell-mediated immunity.
The immunosuppressive activity of 13-cRA included suppres-
sion of interleukin 2, whose production was inhibited in spleno-
cytes. These data indicate that, in an in vivo mammalian sys-
tem, 13-cRA exerts a suppressive activity on T cell-mediated
immunity intensive enough to suppress an ongoing immune re-
sponse, and that this effect can be achieved at nontoxic concen-
trations that may also be attained in human therapy. (J. Clin.
Invest. 1991. 88:1331-1337.) Key words: experimental autoim-
mune encephalomyelitis * central nervous system * isotretinoino
T cell-mediated immunity * immunotherapy
Introduction
Retinoids are the class of natural and synthetic derivatives of
vitamin A. The best known molecule of this class, all-trans-
retinoic acid (RA),V plays a physiological role in morphogenesis
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1. Abbreviations used in this paper: CFA, complete Freund's adjuvant;
EAE, experimental autoimmune encephalomyelitis; ILk2sup, interleu-
kin 2 supernatant(s); MBP, myelin basic protein; p.i., postimmuniza-
tion; RA, all-trans-retinoic acid; 13-cRA, 13-cis-retinoic acid; RAR,
RA receptor; SC, spleen cell; SI, stimulation index.
and cell differentiation. Its 13-cis-isomer (13-cis-retinoic acid,
1 3-cRA), which is better tolerated for systemic administration,
is also used in the therapy ofvarious dermatologic and neoplas-
tic diseases (1-3).
RA (tretinoin), 1 3-cRA (isotretinoin), and other retinoids
have been described to exert a number ofsuppressive activities
on T cell functions, including a decrease in production ofinter-
leukins (IL, 4-15). However, immunostimulatory effects of 13-
cRA and other retinoids on cellular and humoral immunity
have also been reported (16-24). These observations indicate
that the interactions of these molecules with the immune sys-
tem are complex and not completely clarified. Nonetheless, the
established and potential applications of retinoids in human
therapy demand deeper investigation of their effects on the
immune system, particularly at pharmacological concentra-
tions.
In a previous article we reported that experimental autoim-
mune encephalomyelitis (EAE) was suppressed by RA (25).
EAE is an autoimmune disease of the central nervous system
(CNS) inducible in susceptible animals by immunization with
myelin antigens or by passive transfer of sensitized T cells to
syngenic recipients (26-34). EAE induced in Lewis rats has
been used as a generic in vivo model ofautoimmune disorders,
because ofthe ease of detecting and quantitating disease activ-
ity and the consistency with which this rat strain develops a T
cell-mediated delayed-type hypersensitivity-like autoimmune
response (26, 27). In rodents, EAE is mediated by CDV4, CD8-,
and IL-2 receptor-positive T lymphocytes which induce peri-
vascular inflammatory infiltrates in CNS by the end ofthe 2nd
wk postimmunization (p.i.), in accordance with the onset of
neurological signs, whereas encephalitogenic T lymphocytes
can be recovered from peripheral lymphoid organs or periph-
eral blood, beginning 1 wk p.i. (30-34). In passive transfer
EAE, CNS inflammatory infiltrates and neurological signs are
present 5 or 6 d post-transfer of encephalitogenic T lympho-
cytes (30-34).
The suppression of EAE by RA indicates a possible sup-
pressive activity of this drug on immune-mediated diseases,
but its usefulness was limited by its toxicity, and therefore its
possible immunosuppressive activity in the suppression of
EAE was not studied further (25). However, 1 3-cRA, which has
been demonstrated to retain most ofthe pharmacological activ-
ities ofRA, is better tolerated for in vivo administration (1-3).
This finding suggests that 1 3-cRA could represent an optimal
retinoid for experimentation in autoimmune diseases, but the
activity of pharmacological doses of this drug on T cell-me-
diated immunity has not been directly investigated (4).
For these reasons, we studied the in vivo effects ofnontoxic
pharmacological concentrations of 1 3-cRA in EAE, while the
activity of the drug on T cell-mediated immunity was studied
in splenocytes in vitro. We report that 1 3-cRA prevented EAE
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and suppressed T cell response during the efferent phase of the
immune response. The immunosuppression was functional
and reversible, and was obtained at concentrations that can be
achieved in human therapy, without inducing major side ef-
fects.
Methods
Preparation ofthe antigens
Myelin and myelin basic protein (MBP) were purified from guinea pig
spinal cords (Pel Freeze Biologicals, Rogers, AR) according to the
method of Norton and Poduslo (35) and Deibler et al. (36), respec-
tively. The preparations were lyophilized, and stored at -20C.
Induction ofEAE
Female Lewis rats (175-225 g; Charles River Breeding Laboratories,
Inc., Wilmington, MA) were immunized with an emulsion of either (a)
1 mg of guinea pig myelin, dispersed in 0.5 ml of complete Freund's
adjuvant (CFA) containing 3 mg/ml of Mycobacterium tuberculosis
H37RA or (b) 50 Asg ofguinea pig MBP in 0.1 ml ofCFA. The animals
were injected intradermally in both hind foot pads. As "normal" con-
trol, six additional rats were sham-immunized with 0.5 ml of CFA
only.
Assessment ofEAE
Two experiments were designed in order to follow the clinical signs,
and to describe laboratory parameters at day 12 p.i. In experiment 1,
animals were assessed daily for weight and clinical signs for 3 wk. Clini-
cal disease severity was graded on a scale of 1-5 as follows: 0, no signs;
1, tail paralysis; 2, tail paralysis and hind leg weakness; 3, hind leg
paralysis; 4, tetraplegia; 5, death. In experiment 2, the animals were
killed at day 12 p.i. in order to compare laboratory parameters and
clinical signs. Spinal cord and brain were examined for the presence of
perivascular cuffs. The intensity ofthe perivascular infiltrates was arbi-
trarily graded from 1 to 3 by two independent observers. Total DNA
concentration was assayed in the spinal cord, according to Smith et al.
(37), as a parameter of inflammatory cell infiltrates. At the time of
sacrifice, peripheral blood samples were collected. Absolute and rela-
tive lymphocyte counts were carried out using an hemocytometer and
Giemsa stained blood smears.
Spleen cell (SC) response to Con A and antigens
Spleens were collected at day 10 p.i. and passed through a stainless steel
screen mesh. The single cell suspensions were separated from erythro-
cytes in a Ficoll-Hypaque density gradient centrifugation and washed
in HBSS (Flow), resuspended in a final concentration of2 X 106/ml of
RPMI 1640 (Flow) supplemented with 5% heat-inactivated FCS (Flow
Laboratories, Inc., McLean, VA), 1% L-glutamine, 1% Na-pyruvate
(Flow Laboratories, Inc.), 1.25% Hepes buffer (Flow Laboratories,
Inc.), 1% nonessential amino acids, 1% penicillin-streptomycin (Flow
Laboratories, Inc.), and 5 X I0-M 2-mercapoethanol (2-ME). Prolifer-
ative assays in response to 6.25 gg/ml myelin and 50 tg/ml MBP and to
4 ;tg/ml Con A, were carried out in 96-microwell plates using 2 X I0O
cells per well. [3H]thymidine incorporation was measured by scintilla-
tion counting and the magnitude of the proliferative respose was ex-
pressed as mean counts per minute (cpm) or as stimulation indexes (SI;
stimulated culture cpm/unstimulated culture cpm).
Preparation ofIL-2-containing supernatant (IL-2sup)
SC were removed from Lewis rats and cultured at 5 X 106/ml in pres-
ence of 4 ,ug/ml Con A as previously described (38). After 72 h the
IL-2sup were removed, treated with 20 mg/ml a-methyl-mannoside,
and frozen.
IL-2 assay
The IL-2 activity ofthe IL-2sup was assayed using the murine IL-2--de-
pendent cell line, CTL-2 (American Type Culture Collection, Rock-
ville, MD) as previously described (39). Briefly 104 cells per well were
added to 200 ,AI of culture medium containing increasing dilutions of
IL-2sup. 48 h later the cultures were pulsed with [3H]thymidine for an
additional 18 h. Data from two separate experiments were fitted using a
program for analysis of dose-response curves (40). A possible CTLL-2
response to IL-4 was controlled in a separate assay and excluded: up to
50 U/ml of mouse IL-4 did not elicit CTLL-2 proliferation.
Passive transfer ofEAE
Sensitized SC, harvested at day 10 from untreated immunized rats,
were cultured in 24-well plates at a concentration of 5 X 106/ml with 4
,ug/ml Con A for 3 d as previously described (41). After 72 h ofculture,
4 x 107 viable SC per animal were injected i.p. to syngeneic naive
recipients.
13-cRA
13-cRA was kindly provided by Dr. W. Bollag (Hoffmann-LaRoche,
Basel). The powder was aliquoted in oxygen-free vials and stored at
4VC in the dark. Any procedure utilizing 13-cRA was carried out in
dim light.
In vivo studies. On each day of treatment, the 13-cRA was sus-
pended in corn oil and administered by gastric intubation, in two daily
doses; matched controls received the vehicle only. In active EAE the
animals were treated from days 6 to 11 p.i., whereas in passive EAE,
from days I to 6 after the cell transfer. 13-cRA was suspended in corn
oil at a concentration of 7.5 mg/ml. Each rat received 1 ml of suspen-
sion per 200 g ofweight twice a day, in order to administer a total of75
mg/kg per d. At day 5 of treatment (day 10 p.i.), sera from 37 immu-
nized rats were collected at hours 1, 2, 4, 8, and 12 after the morning
administration of the drug. To study the pharmacokinetics, 13-cRA
concentrations were assayed in the serum samples by HPLC as previ-
ously described (42, 43), and the average serum concentration over 24
h was determined.
In vitro studies. 1 3-cRA was dissolved at different concentrations in
dimethyl sulfoxide (DMSO); the stock solutions were then diluted in
the culture medium at 0.01% DMSO final concentration. Control cul-
tures were exposed to 0.01% DMSO only.
Results
In vivo studies. In control rats, the onset of EAE signs was
observed at day 1 1 ± 1 p.i. (Fig. 1, Table I), whereas proliferative
response to the Ag (SI = 4.5), was observed in SC beginning at
day 6 (data not shown). In order to investigate the activity of
1 3-cRA on the effector mechanisms ofthe immune response in
EAE, the animals immunized at day 0 with myelin were there-
fore treated from days 6 to 11 (Fig. 1, Table I), whereas the
animals receiving cell transfer at day 0 were treated from days 1
to 6 (Table II). At day 5 of treatment, 75 mg/kg per d 13-cRA
induced an average serum concentration during 24 h of
5.4±5.2 x 10-6 M.
No major side effects were associated with 13-cRA treat-
ment. In some treated animals a modest degree of weight loss
(always < 10%) was observed (data not shown). No diarrhea or
other signs of gastrointestinal irritation were noted.
As shown in Fig. 1 a delayed and less severe course of the
disease was observed in animals receiving 1 3-cRA. Analysis at
day 12 of the frequency of neurological signs and of the pres-
ence ofinflammatory infiltrates in spinal cords showed that the
disease was significantly suppressed (X2 test: P < 0.001; Table
I). The onset ofneurological signs, observed a few days after the
suspension of the treatment, indicated that discontinuation of
the therapy resulted in partial loss ofthe protective effects (FHg.
1). The highly significant suppression ofDNA concentration in
the spinal cords of the treated animals quantitatively con-
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Figure 1. Effect of 13-cRA on the course of neurological signs in EAE.
1 3-cRA and corn oil were administered from days 6 to 11 after im-
munization for induction of EAE. Each point represents the mean of
nine observations±SE. A delayed and less severe course of EAE is
shown by the group receiving 1 3-cRA. The symptom score is reported
in the text.
firmed the suppression of the inflammatory response in the
CNS (Table I). The characteristic lymphopenia described in
rats during the course ofEAE and during endogenous cortico-
steroid release (44-46) was observed in the vehicle-, but not in
the 13-cRA-treated animals (Table I). In order to establish if
the suppression ofEAE occurred in presence of in vivo effects
of the treatment on T cell functions, lymphocyte response to
Con A was studied at day 10, immediately before the onset of
the disease. At 8 h after the oral administration, when the 13-
cRA serum concentration was 2.8±2.4 X 10-6 M, a lower prolif-
erative response of lymphocytes from the 1 3-cRA-treated ani-
mals was observed (two-tailed Mann-Whitney U test, 2P
= 0.02; Fig. 2).
Table L Effects of13-cRA in Active EAE at Day 12
Inflammatory infiltrates
Perivascular Lymphocyte
Treatment* Neurological signst cuffst DNA counts1l
sg/mg
13-cRA 8/26 (0.8±0.1) 12/26 (0.7) 6.0±0.5 103±17
P<0.001 P<0.001 P<0.001 P<0.001
Oil 25/26 (2.2±0.1) 26/26 (1.7) 9.6±0.1 53±7
* 75 mg/kg per d 1 3-cRA in corn oil or corn oil only from days 6 to
1 1 p.i.
$ The numbers represent the frequency in each group, of animals with
neurological signs or perivascular cuffs in the spinal cord. In paren-
thesis are reported the mean scores of the neurological signs or of the
intensity of the inflammatory infiltrates (X2 test).
Spinal cord mean DNA concentrations expressed as ,ug DNA/mg of
protein ±2 SE. The mean DNA concentration in six sham-immu-
nized animals was 5.6±0.2. (Student's t test).
11 Percentage ±2 SE of the values observed in sham-immunized
animals (mean±2 SE of six observations = 4,416 + 385). (Mann-
Whitney test).
Table IL Effects of13-cRA on EAE Passive Transfer*
Treatment
In vitro In vivoll Neurological signst Perivascular cuflV
DMSO Oil 16/18 18/18
13-cRA Oil 0/12 0/12
DMSO 13-cRA 0/12 0/12
*40 X 106 SC were injected i.p. in syngenic recipients.
$The numbers represent the frequency in each group, ofanimals with
neurological signs or perivascular cuffs in the spinal cord.
I Before transfer, the SC were cultured for 72 h with Con A, in
presence of 0.01% DMSO or 1o06 M 13-cRA dissolved in 0.01 %
DMSO.
11 From days 1 to 6 after cell transfer, 75 mg/kg per d of 13-cRA was
administered in 1 ml of corn oil. Control animals received corn oil
only.
The in vivo activity of 1 3-cRA on the efferent limb of the
immune response was also studied in passive transfer EAE.
Animals treated with the vehicle developed neurological signs
from days 6±1 to 9±1 after transfer, and perivascular cuffs
were observed in spinal cords at day 11 (Table II). By contrast,
animals receiving 1 3-cRA, from days 1 to 6 after cell transfer,
developed neither neurological signs nor perivascular infil-
trates in the spinal cord (Table II).
In vitro studies. In order to assess whether the suppression
of EAE was due to a direct activity of the drug on T cell-me-
diated immunity, we studied in vitro the effects of 1 3-cRA on
SC collected from untreated animals immunized with myelin
or MBP. As shown in Table III, exposure of SC to 13-cRA
concentrations equivalent to or less than those observed in vivo
suppressed lymphocyte proliferation to antigens and to Con A
in a dose-dependent manner. It is noteworthy that the back-
ground proliferations were not affected by the same concentra-
tions of 1 3-cRA, indicating that up to 96 h in vitro exposure to
the drug did not exert direct toxicity in lymphocytes. More-
over, exposure of the SC to 10-6 M 13-cRA during in vitro
activation with Con A, before passive transfer, abrogated the
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Figure 2. In vivo immunosuppressive activity of 13-cRA during the
development ofEAE. Each point represents quadruplicate prolifera-
tions ofSC collected at day 5 oftreatment (day 10 p.i.) and cultured
for 48 h in presence ofConA (SE of < 15% cpm of the mean). When
the serum concentration ofthe drug was 2.8±2.4 x 10-6 M, animals
receiving 13-cRA (o) showed lower lymphocyte proliferation than the
oil treated controls (-); mean±SE: 13-cRA = 252±47; OIL = 355+20;
Mann-Whitney U test: P = 0.02).
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Table III. In Vitro Effects of13-cRA on Ag- and Mitogen-induced SC Proliferation
DMSOt RA 10-8 M RA 10-7 M RA 106M
cpm
Medium* 4,420±5671 5,140±943 2,920+348 6,740±1,130
Exp. 1 Con A 319,000±13,400 (72.2) 114,000±9,140 (22.3) 95,500±15,000 (32.7) 70,600±5,870 (10.5)
Myelin (6.25 usg/ml) 21,000±3,940 (4.8) 11,400±2,530 (2.2) 10,200±1,790 (3.5) 11,500±712 (1.7)
Medium 11,600±3,010 9,630±565 14,700±1,290 5,490±1,030
Exp. 2 Con A 308,000±28,400 (26.4) 228,000±14,700 (23.7) 191,000±19,500 (12.9) ND
Myelin (6.25 ,g/ml) 41,400±7,720 (3.5) 22,400±4,170 (2.3) 19,400±3,020 (1.3) 15,000±2,180 (2.73)
Medium 8,450±2,030 6,390± 1,520 6,650±1,460 7,660±1,390
Exp. 3 Con A 169,000±6,270 (20.0) 93,000±7,110 (14.5) 86,800±6,870 (13.1) 66,500±9,520 (8.7)
MBP (50 ,g/ml) 37,800±4,520 (4.5) 22,400±3,070 (3.5) 23,100±4,790 (3.5) 15,000+2,310 (1.9)
Medium 2,540±422 3,200±545 2,610±278 2,650±4,170
Exp. 4 Con A 139,000±10,200 (54.6) 68,700±3,700 (21.4) 59,000±10,000 (22.6) 50,300±3,460 (18.9)
MBP (50 ,g/ml) 14,800±2,000 (5.8) 2,830±411 (0.9) 3,410±483 (1.3) 2,810±292 (1.1)
* Myelin, MBP, and Con A were dissolved in the culture medium at 6.25, 50, and 4 jg/ml, respectively. Eachculture contained 0.01%
DMSO. I The values express cpm±SE of quadruplicate cultures. Stimulation indices (SI) are reported in parenthesis. The cells were collected
from rats immunized with myelin in experiments 1 and 2, and with MBP in experiments 3 and 4.
capacity ofencephalitogenic lymphocytes to transfer EAE (Ta-
ble II).
The previous experiments, indicating that T cell-mediated
immunity is at least one of the targets of the immunological
activity of 13-cRA, led us to study the effect of 13-cRA on
lymphokine production by T cells. As expected, IL-2sup pre-
pared in the presence of 10-6 M 13-cRA showed a lower IL-2
activity, expressed as the proliferation ofthe IL-2-dependent T
cell line CTLL-2, compared to control IL-2sup (P = 0.048, Fig.
3). However, the proliferation ofthe CTLL-2 induced by opti-
mal dilutions of IL-2sup was not inhibited by the addition of
10-6 M 13-cRA (data not shown). Suppression ofIL-2 produc-
x
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Figure 3. Suppression of IL-2 production in presence of 10'- M 13-
cRA. The curves represent the response ofthe IL-2-dependent T cell
line CTLL-2 to percent dilutions of IL-2 sup produced by SC in
presence of 10-6 M 13-cRA (RA IL-2sup, o), and to control IL-2sup
(.). The dilution ofRA IIH2sup exerting 50% of the maximal activity
(ED50) was significantly higher (mean±SE = 1.65%±0.21) than the
control ED,0 (0.88%±0.l 1; P = 0.048).
tion, but not of IL-2 activity, is therefore one effect of 1 3-cRA
on T cell-mediated immunity.
Finally, the effects of different times of exposure to 10-6 M
1 3-cRA were examined in proliferating T lymphocytes during
a standard 96-h stimulation assay in presence of Con A. 13-
cRA reduced a SC proliferative response to the mitogen in a
time-dependent manner, if it was added duringthe first 48 h of
the assay, but did not show any effect ifthe Con A-stimulated
SC were exposed to 13-cRA during the second 48 h (Fig. 4).
This experiment demonstrates that exposure to 10-6 M 13-
cRA for up to 48 h does not affect viability ofstimulated proli-
ferating lymphocytes., Because under these experimental con-
ditions at least one mitotic cycle is completed in 48 h, thymi-
dine incorporation equivalent to 100% of the untreated
cultures, indicate absence of antimitotic activity of the drug.
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Figure 4. Effects of different times of exposure of SC to 106 M 13-
cRA during a standard proliferation assay with Con A. Triplicate
96-h cultures were exposed to 13-cRA starting from the hour indi-
cated on abscissa: each point represents the percentage proliferation
ofthe 13-cRA exposed cultures in respect to control cultures not ex-
posed to 13-cRA. (A-cpm of 13-cRA exposed cultures/A-cpm of
DMSO-exposed cultures x 100). 13-cRA suppresses the response to
the mitogen in a time-dependent manner if added during the first
part of the assay, but has no effect if added during the last 48 h.
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Discussion
We have studied the effects of 1 3-cRA on in vivo and in vitro
models of cellular immunity, at concentrations that are well
tolerated in human therapy (1-3, 47-50). 13-cRA administra-
tion during the development of the efferent limb of the im-
mune response significantly suppressed the clinical and histo-
pathological signs ofactive EAE. Suppression was almost com-
plete as long as the animals received 1 3-cRA, whereas
discontinuation ofthe treatment resulted in a loss ofthe protec-
tive effect. However, passive transfer EAE was completely pre-
vented and discontinuation of 1 3-cRA 6 d after passive transfer
resulted in no late disease.
In these experiments, suppression ofEAE was achieved us-
ing a treatment protocol that was not associated with major
side effects and that induced serum concentrations equivalent
to the highest reported to be tolerated in human therapy. Ad-
ministration ofdrug boluses through gastric intubation permit-
ted a precise control of the dosages, but did not allow an opti-
mal absorption of the drug. For this reason and because ofthe
high turnover rate of 13-cRA described in rodents (1-3), high
oral dosages were required to achieve the desired serum con-
centrations. Preliminary experiments indicated that diarrhea
and other signs ofgastrointestinal intolerance (e.g., accelerated
weight loss) developed in some animals by day 7 of 13-cRA
therapy. For this reason a 6-d treatment regimen was selected.
In humans, equivalent serum concentrations can be reached
using much lower dosages of 13-cRA and such regimens are
well tolerated even during chronic administration (47-50).
The response of SC to the T cell mitogen Con A was also
inhibited during the treatment, indicating that the suppression
of the disease occurred in presence of in vivo inhibition of T
cell functions. The possibility that this inhibition was not func-
tional but resulted from a direct lymphocytotoxic activity of
the drug was excluded by the observation that, at day 7 from
the beginning of the treatment, animals receiving 1 3-cRA had
the same number of circulating lymphocytes as the "normal"
controls which were sham-immunized withCFA only. The pos-
sibility that subclinical toxicity of 13-cRA may have induced
release of endogenous corticosteroids was investigated using
peripheral blood lymphocyte count as a marker: indeed, in rats
exposed to stress, high levels ofcorticosteroids are secreted and
a corresponding lymphopenia is usually observed (44-46, 51).
In the present experiments, the rats treated with 13-cRA
showed lymphocyte counts equivalent to the sham-immunized
rats injected only with CFA, whereas the animals receiving
corn oil showed the usual lymphopenia described in EAE (Ta-
ble I, reference 46). This observation indicates that the 1 3-cRA
administration did not induce relevant endogenous corticoste-
roid release, and therefore that the suppression of the disease
was directly due to the treatment. The immunosuppressive ac-
tivity of 1 3-cRA was also observed in vitro. Continuous expo-
sure to 1 3-cRA concentrations equivalent to or less than those
observed in vivo during EAE, suppressed Con A- and Ag-in-
duced lymphocyte proliferation in a dose- and time-dependent
manner, with maximal activity at 10-6 M (Table III), which
decreased as a function of time when added after the lympho-
cyte activation (Fig. 4). This concentration prevented passive
transfer of EAE by encephalytogenic lymphocytes (Table II)
and reduced IL-2 production (Fig. 3) without lymphocytotoxic
effect in vivo (Table I) as well as in vitro (Fig. 4). Taken alto-
gether, the data reported in this paper indicate that pharmaco-
logical concentrations of 1 3-cRA are immunosuppressive and
can prevent an ongoing T cell-mediated autoimmune disease
even when administered exclusively during the development of
the efferent limb ofthe immune response. An immunosuppres-
sive activity intensive enough to control an ongoing immune
response is shown also by cyclosporine A but not by cytotoxic
drugs (52, 53). These drugs can suppress EAE ifgiven prophy-
lactically, but not ifadministered when the immune system has
already mounted an effector response (53). It is likely that 13-
cRA treatment does not specifically delete clones ofAg-respon-
sive T cells, and the immunosuppressive activity is probably
due to a nonspecific effect on one or more subpopulations of
immunocompetent cells, which include suppression of IL-2
production. Indeed, the described activities of 13-cRA on T
cell-mediated immunity and IL-2 production were observed
stimulating an unselected SC population which included acces-
sory cells such as macrophages and dendritic cells. In addition,
suppressive activities of RA on accessory cell functions has
been previously described (14, 54), suggesting that 1 3-cRA ac-
tivity on IL-2 production as well as on T cell proliferation,
could in part be indirect and mediated by an effect on accessory
cells. The suppression of the T cell proliferative response as
well as of IL-2 production, could be therefore due to a direct
effect of 13-cRA on T-lymphocytes or could be indirect and
mediated by other soluble factors produced by a number of
immunocompetent cells. It is noteworthy, for example, that
RA stimulates the production oftransforming growth factor-3,
one ofthe most powerful immunosuppressive cytokines, which
is produced by many immunocompetent and nonimmuno-
competent cells (55, 56). Nonetheless, the possibility ofa direct
effect of 1 3-cRA on IL-2 production by T lymphocytes is indi-
rectly suggested by the reported inhibition by RA ofdiacylgly-
cerol induced ornithine-decarboxylase activity, an early event
that plays a key role in T lymphocyte activation (5-7). In addi-
tion, the described supression of IL-2 production is consistent
with the recent observation that another experimental retinoid,
Ro 15-0778 (temarotene, Hoffmann-LaRoche, Basel), inhibits
phytohemagglutinin-induced production of IL-2 and IFN-
gamma in human T-lymphocytes (W. Bollag, personal commu-
nication). Temarotene has also been reported to exert a marked
therapeutic activity on lichen planus, a human T cell-me-
diated dermatological disease (57). The possibility that 1 3-cRA
acts on multiple targets of the immune activity must therefore
be taken into account when results obtained under different
experimental conditions are compared and may at least in part
explain the large number of confficting results reported in the
literature (for review, see reference 4).
The similar pharmacological activities of RA and 1 3-cRA
and the existence of an intracellular retinoic acid binding pro-
tein that binds both these retinoids (58) suggest that the two
isomers could act through a common receptor. Five different
RA receptors (RARs), each one encompassing multiple iso-
forms, have been so far described (59-67). At least three of
these receptors bind RA as well as other natural and synthetic
retinoids (59-62), including 13-cRA (63), although with less
affinity. In addition, some degree of cis-trans isomerization to
RA may in part contribute to the activity of 13-cRA. The
RARs are differentially expressed in various tissues and exhibit
different affinities for RA and other retinoids (59, 64), suggest-
ing that they may have distinct roles in mediating a number of
different activities ofthese molecules. Very few genes activated
by the RARs are known so far (61, 64,65), but it is noteworthy
Immunosuppressive Activity of13-cis-Retinoic Acid 1335
that these receptors are highly conserved from rodents to hu-
mans and are expressed in both human and rat spleen, and that
the optimal RA concentration inducing maximal transcription
by the RARs is 10-6 M (59, 60, 63-66), the same nontoxic
concentration that we have shown to be active on T cell-me-
diated immunity. In addition, RARs are part of a superfamily
ofnuclear receptors that also mediate the activity ofsteroid and
thyroid hormones (67), supporting the hypothesis that RA
functions in a fashion analogous to these hormones. Moreover,
it must be emphasized that steroid and thyroid hormones can
repress gene expression as well as activate it (67). It is possible
therefore to hypothesize that, like glucocorticoids, 1 3-cRA ex-
erts suppressive activity on T cell-mediated immunity through
a receptor whose expression varies in different cell populations
and under different experimental conditions. Nonetheless, the
observations presented in this article establish that, in an in
vivo mammalian system, the net result of 1 3-cRA activity is a
suppressive effect on T cell-mediated immune response, and
that this activity is intensive enough to suppress an ongoing
immune response at nontoxic concentrations which may also
be reached in human therapy. Considering that the serum con-
centrations of 1 3-cRA induced in this study can be chronically
maintained in human therapy with minor side effects (1-3,
47-50), the experimental use of 1 3-cRA also in human chronic
T cell-mediated autoimmune diseases can now be proposed.
In addition, the prevention ofEAE, a model ofhuman T cell-
mediated disease of the CNS (27), and the excellent bioavail-
ability in the CNS of retinoids (68, 69), suggest that multiple
sclerosis patients could constitute an appropriate population
for a phase 1 clinical trial.
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